Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 09:48AM ET
1.36
Dollar change
-0.04
Percentage change
-2.76
%
Index- P/E- EPS (ttm)-4.15 Insider Own40.04% Shs Outstand11.70M Perf Week-2.76%
Market Cap15.92M Forward P/E- EPS next Y- Insider Trans-0.00% Shs Float7.01M Perf Month-5.89%
Income-44.20M PEG- EPS next Q- Inst Own38.51% Short Float0.74% Perf Quarter-1.36%
Sales2.78M P/S5.73 EPS this Y- Inst Trans254.72% Short Ratio4.97 Perf Half Y-15.97%
Book/sh1.12 P/B1.21 EPS next Y- ROA-101.61% Short Interest0.05M Perf Year-52.57%
Cash/sh1.66 P/C0.82 EPS next 5Y- ROE-156.44% 52W Range1.22 - 5.12 Perf YTD-64.64%
Dividend Est.- P/FCF- EPS past 5Y21.95% ROI-337.22% 52W High-73.40% Beta0.81
Dividend TTM- Quick Ratio2.71 Sales past 5Y57.51% Gross Margin7.60% 52W Low11.58% ATR (14)0.06
Dividend Ex-Date- Current Ratio2.71 EPS Y/Y TTM67.35% Oper. Margin-901.15% RSI (14)42.05 Volatility3.84% 4.47%
Employees6 Debt/Eq0.00 Sales Y/Y TTM292.23% Profit Margin-1591.75% Recom3.00 Target Price1.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q99.63% Payout- Rel Volume0.03 Prev Close1.40
Sales Surprise- EPS Surprise94.44% Sales Q/Q-100.00% EarningsNov 12 AMC Avg Volume10.39K Price1.36
SMA20-3.04% SMA50-4.69% SMA200-14.41% Trades Volume31 Change-2.76%
Date Action Analyst Rating Change Price Target Change
Nov-24-21Upgrade Oppenheimer Perform → Outperform $7
Aug-21-19Downgrade Oppenheimer Outperform → Perform
Apr-30-19Initiated Jefferies Buy $18
Dec-13-18Initiated Chardan Capital Markets Buy $20
Mar-19-18Initiated H.C. Wainwright Buy $20
Jan-29-18Initiated Piper Jaffray Overweight $16
Nov-12-24 04:35PM
Aug-09-24 09:33AM
Aug-08-24 07:00AM
Aug-01-24 11:42AM
May-23-24 03:29PM
01:54PM Loading…
May-14-24 01:54PM
07:00AM
Mar-19-24 08:10AM
07:00AM
Feb-20-24 12:15PM
Feb-09-24 09:41AM
08:42AM
05:47AM
Feb-08-24 04:15PM
Feb-02-24 12:00PM
08:47AM Loading…
Jan-16-24 08:47AM
Jan-04-24 07:00AM
Dec-27-23 07:00AM
Dec-07-23 07:00AM
Nov-14-23 08:55AM
Nov-09-23 07:19AM
07:00AM
Nov-07-23 07:00AM
Nov-02-23 10:00AM
Oct-03-23 04:15PM
Sep-29-23 07:00AM
Sep-28-23 11:15AM
09:13AM
Sep-27-23 12:30PM
Sep-21-23 07:00AM
11:00AM Loading…
Sep-19-23 11:00AM
Aug-10-23 08:40AM
07:00AM
Jul-11-23 07:00AM
Jun-28-23 07:00AM
Jun-27-23 07:00AM
Jun-08-23 06:45AM
Jun-05-23 06:45AM
May-24-23 06:35AM
May-23-23 06:50AM
May-13-23 08:21AM
May-11-23 12:38PM
08:05AM
06:50AM
May-09-23 07:15AM
06:50AM
May-04-23 10:00AM
Apr-28-23 05:12PM
Mar-29-23 07:55AM
06:40AM
Mar-28-23 06:52AM
Mar-20-23 06:55AM
Mar-10-23 08:35AM
Mar-08-23 07:00AM
Mar-07-23 08:35AM
06:57AM
Jan-24-23 06:57AM
Jan-19-23 06:58AM
Jan-17-23 10:00AM
Jan-16-23 12:00PM
Jan-14-23 07:17AM
Jan-05-23 06:58AM
Jan-03-23 06:58AM
Dec-15-22 10:49AM
06:59AM
Dec-04-22 09:27AM
Nov-30-22 04:15PM
Nov-10-22 08:05AM
06:59AM
Oct-18-22 11:15AM
06:59AM
Sep-06-22 07:00AM
Aug-23-22 07:00AM
Aug-11-22 03:50PM
08:15AM
07:05AM
06:58AM
Jul-28-22 07:00AM
Jul-12-22 07:00AM
Jun-29-22 07:00AM
Jun-28-22 07:00AM
Jun-27-22 10:06AM
Jun-21-22 07:00AM
Jun-01-22 07:00AM
May-24-22 07:00AM
May-12-22 10:51AM
08:35AM
07:00AM
May-05-22 07:00AM
Apr-28-22 07:00AM
Apr-26-22 07:00AM
Apr-01-22 07:00AM
Mar-17-22 08:25AM
07:00AM
Mar-10-22 07:00AM
Mar-03-22 07:00AM
Feb-24-22 07:00AM
Feb-08-22 07:00AM
Jan-11-22 08:59AM
Jan-06-22 07:00AM
Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dooley Mary BethHead of FinanceOct 29 '24Sale1.407911115,152Oct 30 07:21 PM
Dooley Mary BethHead of FinanceApr 02 '24Sale1.7318832515,231Apr 04 04:00 PM
Awad AntoineChief Operating OfficerApr 02 '24Sale1.7337264433,859Apr 04 04:00 PM